Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Zacks Investment Research to Sell

Y-mAbs Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Y-mAbs Therapeutics Downgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of Y-mAbs Therapeutics traded up $0.02 on Tuesday, reaching $27.32. 0 shares of the stock traded hands, compared to its average volume of 154383. Shares of Y-mAbs Therapeutics were trading at $27.32 on Tuesday. The firm’s 50 day moving average is $30.27 and its 200 day moving average is $34.82.Y-mAbs Therapeutics has a 12 month low of $26.55 and a 12 month high of $55.22. While on yearly highs and lows, Y-mAbs Therapeutics’s today has traded high as $27.68 and has touched $26.55 on the downward trend. See More Analyst Rating at: RATING

Y-mAbs Therapeutics Earnings and What to expect: 

Y-mAbs Therapeutics last issued its quarterly earnings data on August 5th, 2021. The reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.15. The company had revenue of $10.95 million for the quarter, compared to analyst estimates of $7.66 million. Y-mAbs Therapeutics has generated ($2.97) earnings per share over the last year (($1.09) diluted earnings per share). Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($1.05) to ($0.75) per share. Y-mAbs Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($1.05) to ($0.75) per share. The P/E ratio of Y-mAbs Therapeutics is -25.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Y-mAbs Therapeutics is -25.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Y-mAbs Therapeutics has a P/B Ratio of 10.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Y-mAbs Therapeutics (NASDAQ:YMAB) Moving Average Technical Analysis

5 day Moving Average is $27.61 And 5 day price change is -$0.68 (-2.43%)  with average volume for 5 day average is 99,140. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $29.42 and 20 day price change is -$5.91 (-17.79%) and average 20 day moving volume is 156,820. 50 day moving average is $30.27  and 50 day price change is -$6.98 ( -20.35%)  and with average volume for 50 days is : 202,804. 200 day moving average is $34.82  and 200 day price change is -$26.18 (-48.93%)  and with average volume for 200 days is : 257,264.

Other owners latest trading in Y-mAbs Therapeutics :

  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 47,474 which equates to market value of $1.61M and appx 0.00% owners of Y-mAbs Therapeutics
  • On 8/26/2021 shares held by Ashford Capital Management Inc. were 583,508 which equates to market value of $19.72M and appx 1.80% owners of Y-mAbs Therapeutics
  • On 8/25/2021 shares held by Marshall Wace LLP were 12,310 which equates to market value of $0.42M and appx 0.00% owners of Y-mAbs Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 59.81% for Y-mAbs Therapeutics

See More Analyst Rating at: RATING